Trial Profile
EXTRA - evaluation of xeloda treatment with radiotherapy in anal cancer. A mulitcentre phase II study of chemoradiation and oral xeloda [capecitabine] and mitomycin C for patients with anal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Mitomycin
- Indications Anal cancer
- Focus Therapeutic Use
- Acronyms EXTRA
- 16 Mar 2010 Planned number of patients changed from 10 to 30 and lead trial investigator (Glynne-Jones R) added as reported by United Kingdom Clinical Research Network.
- 25 Oct 2005 New trial record.